© Copyright 2004-2014 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        

 
Detailed reports about
PharmaInformatic
published in
several newspapers
(read more..)



      Get In Contact


Direct access to all pages:



Site map

PharmaInformatic is a German biotech company, which provides ADME Knowledge Bases and predictive tools (Expert Systems) to improve drug discovery and development. The company was founded in 2004 by Dr. Wolfgang Boomgaarden and is based in Emden, Germany.
 

Current News:

Research collaboration with AVIVIA BV to evaluate and prioritise novel prodrugs for the treatment of cancer based on estimated oral bioavailability in humans (more).

UNIZYME Laboratories A/S and PharmaInformatic enter into a collaboration for the development of new therapeutic agents for the treatment of inflammatory and autoimmune diseases (more).

BRIDGE BIORESEARCH PLC and PharmaInformatic have signed a collaboration agreement.
Prediction of oral bioavailability of drug candidates for the treatment of Type 2 diabetes by using IMPACT-F (more).

 

Prediction of oral bioavailability in humans (IMPACT-F):

A novel expert system to accelerate drug discovery is now available. The expert system IMPACT-F calculates oral bioavailability of future drugs in humans. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. Read our current research results on bioavailability of drugs.


Computational models such as IMPACT-F replace animal trials: they require no experimental effort and results are almost immediately available. Since they are significantly more reliable than animal models, they increase the prospects of successful clinical trials in humans.
 

Largest knowledge base on bioavailability of drugs worldwide (PACT-F):

PharmaInformatic has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of new drugs. The development of the knowledge base began in 2005. Since then the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database (more).


PACT-F is now the largest knowledge base on bioavailability worldwide. It contains 8296 records, which describe in detail the results of clinical trials in humans and preclinical trials in animals, see content of PACT-F.

Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development can be stopped. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market.